Astellas US LLC et al v. Glenmark Pharmaceuticals Limited
| Gilead Sciences, Inc., Astellas US LLC and Astellas Pharma US, Inc. |
| Glenmark Pharmaceuticals Limited |
| 1:2020cv00516 |
| April 15, 2020 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on June 11, 2020. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Pro Hac Vice Attorney Joseph M. Reisman for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Pro Hac Vice Attorney Ben Katzenellebogen for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Pro Hac Vice Attorney William R. Zimmerman for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Pro Hac Vice Attorney Kimberly A. Kennedy for Glenmark Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr) |
| Filing 12 ANSWER to #10 Answer to Complaint, Counterclaim to Defendant's Counterclaim by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Oakes, Robert) |
| Filing 11 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Green, James) |
| Filing 10 ANSWER to #1 Complaint, of Glenmark Pharmaceuticals Limited, COUNTERCLAIM against All Plaintiffs by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Green, James) |
| Filing 9 MOTION for Pro Hac Vice Appearance of Attorney Ben Katzenellebogen, Joseph Reisman, Kimberly A. Kennedy and William R. Zimmerman - filed by Glenmark Pharmaceuticals Limited. (Attachments: #1 Certification of Ben Katzenellebogen, #2 Certification of Joseph Reisman, #3 Certification of Kimberly Kennedy, #4 Certification of William R. Zimmerman)(Green, James) |
SO ORDERED, re #9 MOTION for Pro Hac Vice Appearance of Attorney Ben Katzenellebogen, Joseph Reisman, Kimberly A. Kennedy and William R. Zimmerman filed by Glenmark Pharmaceuticals Limited. Signed by Judge Colm F. Connolly on 6/2/2020. (fms)
|
| Filing 8 STIPULATION TO EXTEND TIME for Defendant to move, answer, or otherwise respond to the Complaint to June 8, 2020 - filed by Glenmark Pharmaceuticals Limited. (Green, James) |
|
SO ORDERED, re #8 STIPULATION TO EXTEND TIME for Defendant to move, answer, or otherwise respond to the Complaint to June 8, 2020 filed by Glenmark Pharmaceuticals Limited, Set/Reset Answer Deadlines: Glenmark Pharmaceuticals Limited answer due 6/8/2020. Signed by Judge Colm F. Connolly on 5/6/2020. (fms)
|
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) |
| Filing 7 SUMMONS Returned Executed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc.. Glenmark Pharmaceuticals Limited served on 4/17/2020, answer due 5/8/2020. (Oakes, Robert) |
| No Summons Issued. (mal) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gilead Sciences, Inc.. (mal) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Astellas US Holding, Inc. for Astellas Pharma US, Inc., Astellas US LLC. Astellas Pharma Inc. is the sole shareholder of Astellas US Holding, Inc. filed by Astellas Pharma US, Inc., Astellas US LLC. (mal) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,106,183 ;US RE 47,301 E ;US 8,524,883. (mal) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 2, 2020. Date of Expiration of Patent: February 2, 2027.Thirty Month Stay Deadline: October 2, 2022. (mal) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mal) |
| Filing 1 COMPLAINT FOR PATENT INFRINGEMENT - filed against Glenmark Pharmaceuticals Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2900469.) - filed by Astellas US LLC, Gilead Sciences, Inc., Astellas Pharma US, Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Civil Cover Sheet)(mal) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
